Bibliographic details
Shiroiwa T, Fukuda T, Tsutani K. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. International Journal of Clinical Oncology 2010; 15(3) : 256-262
MeSH
Aged; Angiogenesis Inhibitors /administration & Antibodies, Monoclonal /administration & Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols /administration & Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms /drug therapy /economics /mortality /secondary; Cost Sharing; Cost-Benefit Analysis; Deoxycytidine /administration & Disease-Free Survival; Drug Costs; Financing, Personal; Fluorouracil /administration & Humans; Japan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome; derivatives /economics; derivatives /economics; dosage /analogs & dosage /analogs & dosage /economics; dosage /economics; dosage /economics